Lineage Cell Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Lineage Cell Therapeutics, Inc. (LCTX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $272.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $272.00K, a 700.00% increase year-over-year.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $40.00K.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $735.00K.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $847.00K, a 41.88% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $597.00K.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.29M, a 973.24% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $272.00K 10-Q · filed 2026-08-06 | $312.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $272.00K 10-Q · filed 2026-05-12 | $312.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.05M derived: sum of 3 quarters · filed 2026-05-12 | $1.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $775.00K derived: sum of 2 quarters · filed 2026-03-05 | $813.00K derived: sum of 3 quarters · filed 2026-08-06 | $847.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $735.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $773.00K derived: sum of 2 quarters · filed 2026-08-06 | $807.00K 10-Q · filed 2025-11-06 | $807.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $72.00K 10-Q · filed 2026-08-06 | $72.00K derived: sum of 3 quarters · filed 2026-08-06 | $72.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $34.00K 10-Q · filed 2026-05-12 | $34.00K derived: sum of 2 quarters · filed 2026-05-12 | $34.00K derived: sum of 3 quarters · filed 2026-05-12 | $34.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $597.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $597.00K 10-Q · filed 2025-11-06 | $597.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $597.00K 10-Q · filed 2025-08-12 | $597.00K derived: sum of 3 quarters · filed 2025-08-12 | $597.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $597.00K 10-Q · filed 2025-05-13 | $597.00K derived: sum of 2 quarters · filed 2025-05-13 | $597.00K derived: sum of 3 quarters · filed 2025-05-13 | $597.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $0.00 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $1.26M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $1.26M derived: sum of 3 quarters · filed 2024-08-08 | $2.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $1.26M derived: sum of 2 quarters · filed 2024-05-09 | $2.25M derived: sum of 3 quarters · filed 2024-05-09 | $2.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $2.25M derived: sum of 2 quarters · filed 2024-03-07 | $2.25M derived: sum of 3 quarters · filed 2024-03-07 | $2.29M 10-K · filed 2024-03-07 |
| 2022-09-30 | $995.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $995.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.03M 10-Q · filed 2023-11-09 | $1.21M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $33.00K 10-Q · filed 2023-08-10 | $214.00K derived: sum of 3 quarters · filed 2023-08-10 | $214.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-11 | $214.00K derived: sum of 2 quarters · filed 2023-05-11 | $214.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $181.00K derived: sum of 2 quarters · filed 2023-03-09 | $213.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $32.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $32.00K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.02M derived: sum of 2 quarters · filed 2022-03-10 | $1.02M derived: sum of 3 quarters · filed 2022-03-10 | $1.05M 10-K · filed 2022-03-10 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $29.00K 10-Q · filed 2021-11-10 | $678.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $29.00K 10-Q · filed 2021-08-12 | $678.00K derived: sum of 3 quarters · filed 2021-08-12 | $678.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $29.00K 10-Q · filed 2021-05-13 | $678.00K derived: sum of 2 quarters · filed 2021-05-13 | $678.00K derived: sum of 3 quarters · filed 2021-05-13 | -$3.91M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $649.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $649.00K derived: sum of 2 quarters · filed 2021-03-11 | -$3.94M derived: sum of 3 quarters · filed 2021-03-11 | $738.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$4.59M derived: sum of 2 quarters · filed 2020-11-04 | $89.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$4.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $89.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $4.68M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |